Drug Profile


Alternative Names: ASP 4130; AV-951; Fotivda; Kil8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AVEO Oncology; EUSA Pharma; Institute Gustave-Roussy; Kyowa Hakko Kirin; Pharmstandard
  • Class Antineoplastics; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Registered Renal cell carcinoma
  • Phase I Solid tumours
  • Suspended Breast cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 09 Nov 2017 Adverse events data from phase I portion of the phase I/II TiNivo trial in Renal cell carcinoma released by AVEO Oncology and Eusa pharma
  • 20 Sep 2017 Safety data from phase I portion of the phase I/II TiNivo trial in Renal cell carcinoma released by AVEO Oncology
  • 28 Aug 2017 Registered for Renal cell carcinoma (First-line therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in European Union, Norway, Iceland, Liechtenstein (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top